ID   ATTY_HUMAN              Reviewed;         454 AA.
AC   P17735; B2R8I1; D3DWS2;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1990, sequence version 1.
DT   12-APR-2017, entry version 174.
DE   RecName: Full=Tyrosine aminotransferase;
DE            Short=TAT;
DE            EC=2.6.1.5;
DE   AltName: Full=L-tyrosine:2-oxoglutarate aminotransferase;
GN   Name=TAT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1973834; DOI=10.1093/nar/18.13.3853;
RA   Rettenmeier R., Natt E., Zentgraf H., Scherer G.;
RT   "Isolation and characterization of the human tyrosine aminotransferase
RT   gene.";
RL   Nucleic Acids Res. 18:3853-3861(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7908801;
RA   Zelenin S.M., Mertvetsov N.P.;
RT   "Nucleotide sequence of the human tyrosine aminotransferase gene.";
RL   Bioorg. Khim. 20:196-204(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND CATALYTIC ACTIVITY.
RC   TISSUE=Liver;
RX   PubMed=7999802;
RA   Seralini G.E., Luu-The V., Labrie F.;
RT   "Cloning and expression of human tyrosine aminotransferase cDNA.";
RL   Biochim. Biophys. Acta 1260:97-101(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ILE-294.
RX   PubMed=16640556; DOI=10.1111/j.1742-4658.2006.05202.x;
RA   Sivaraman S., Kirsch J.F.;
RT   "The narrow substrate specificity of human tyrosine aminotransferase
RT   -- the enzyme deficient in tyrosinemia type II.";
RL   FEBS J. 273:1920-1929(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-448, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 38-444 IN COMPLEX WITH
RP   PYRIDOXAL PHOSPHATE.
RG   Structural genomics consortium (SGC);
RT   "Human tyrosine aminotransferase.";
RL   Submitted (AUG-2008) to the PDB data bank.
RN   [9]
RP   VARIANT TYRSN2 VAL-362.
RX   PubMed=1357662; DOI=10.1073/pnas.89.19.9297;
RA   Natt E., Kida K., Odievre M., di Rocco M., Scherer G.;
RT   "Point mutations in the tyrosine aminotransferase gene in tyrosinemia
RT   type II.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:9297-9301(1992).
CC   -!- FUNCTION: Transaminase involved in tyrosine breakdown. Converts
CC       tyrosine to p-hydroxyphenylpyruvate. Can catalyze the reverse
CC       reaction, using glutamic acid, with 2-oxoglutarate as cosubstrate
CC       (in vitro). Has much lower affinity and transaminase activity
CC       towards phenylalanine. {ECO:0000269|PubMed:16640556,
CC       ECO:0000269|PubMed:7999802}.
CC   -!- CATALYTIC ACTIVITY: L-tyrosine + 2-oxoglutarate = 4-
CC       hydroxyphenylpyruvate + L-glutamate. {ECO:0000269|PubMed:16640556,
CC       ECO:0000269|PubMed:7999802}.
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC   -!- PATHWAY: Amino-acid degradation; L-phenylalanine degradation;
CC       acetoacetate and fumarate from L-phenylalanine: step 2/6.
CC   -!- SUBUNIT: Homodimer. {ECO:0000305|Ref.8}.
CC   -!- INTERACTION:
CC       P15104:GLUL; NbExp=3; IntAct=EBI-12046643, EBI-746653;
CC       Q05086-3:UBE3A; NbExp=8; IntAct=EBI-12046643, EBI-11026619;
CC   -!- DISEASE: Tyrosinemia 2 (TYRSN2) [MIM:276600]: An inborn error of
CC       metabolism characterized by elevations of tyrosine in the blood
CC       and urine, and oculocutaneous manifestations. Typical features
CC       include palmoplantar keratosis, painful corneal ulcers, and mental
CC       retardation. {ECO:0000269|PubMed:1357662}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the class-I pyridoxal-phosphate-dependent
CC       aminotransferase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52520; CAA36750.1; -; mRNA.
DR   EMBL; X52509; CAA36749.1; -; Genomic_DNA.
DR   EMBL; X52510; CAA36749.1; JOINED; Genomic_DNA.
DR   EMBL; X52511; CAA36749.1; JOINED; Genomic_DNA.
DR   EMBL; X52512; CAA36749.1; JOINED; Genomic_DNA.
DR   EMBL; X52513; CAA36749.1; JOINED; Genomic_DNA.
DR   EMBL; X52514; CAA36749.1; JOINED; Genomic_DNA.
DR   EMBL; X52515; CAA36749.1; JOINED; Genomic_DNA.
DR   EMBL; X52516; CAA36749.1; JOINED; Genomic_DNA.
DR   EMBL; X52517; CAA36749.1; JOINED; Genomic_DNA.
DR   EMBL; X52518; CAA36749.1; JOINED; Genomic_DNA.
DR   EMBL; X52519; CAA36749.1; JOINED; Genomic_DNA.
DR   EMBL; X55675; CAA39210.1; -; mRNA.
DR   EMBL; AK313380; BAG36178.1; -; mRNA.
DR   EMBL; CH471166; EAW59230.1; -; Genomic_DNA.
DR   EMBL; CH471166; EAW59231.1; -; Genomic_DNA.
DR   CCDS; CCDS10903.1; -.
DR   PIR; S10887; S10887.
DR   RefSeq; NP_000344.1; NM_000353.2.
DR   UniGene; Hs.161640; -.
DR   PDB; 3DYD; X-ray; 2.30 A; A/B=41-444.
DR   PDBsum; 3DYD; -.
DR   ProteinModelPortal; P17735; -.
DR   SMR; P17735; -.
DR   BioGrid; 112761; 4.
DR   IntAct; P17735; 4.
DR   STRING; 9606.ENSP00000348234; -.
DR   ChEMBL; CHEMBL3043; -.
DR   DrugBank; DB00142; L-Glutamic Acid.
DR   DrugBank; DB00120; L-Phenylalanine.
DR   DrugBank; DB00135; L-Tyrosine.
DR   DrugBank; DB00114; Pyridoxal Phosphate.
DR   iPTMnet; P17735; -.
DR   PhosphoSitePlus; P17735; -.
DR   BioMuta; TAT; -.
DR   DMDM; 114713; -.
DR   MaxQB; P17735; -.
DR   PaxDb; P17735; -.
DR   PeptideAtlas; P17735; -.
DR   PRIDE; P17735; -.
DR   DNASU; 6898; -.
DR   Ensembl; ENST00000355962; ENSP00000348234; ENSG00000198650.
DR   GeneID; 6898; -.
DR   KEGG; hsa:6898; -.
DR   UCSC; uc002fap.3; human.
DR   CTD; 6898; -.
DR   DisGeNET; 6898; -.
DR   GeneCards; TAT; -.
DR   HGNC; HGNC:11573; TAT.
DR   MalaCards; TAT; -.
DR   MIM; 276600; phenotype.
DR   MIM; 613018; gene.
DR   neXtProt; NX_P17735; -.
DR   OpenTargets; ENSG00000198650; -.
DR   Orphanet; 28378; Tyrosinemia type 2.
DR   PharmGKB; PA36338; -.
DR   eggNOG; KOG0259; Eukaryota.
DR   eggNOG; COG0436; LUCA.
DR   GeneTree; ENSGT00650000093238; -.
DR   HOGENOM; HOG000239005; -.
DR   HOVERGEN; HBG004318; -.
DR   InParanoid; P17735; -.
DR   KO; K00815; -.
DR   OMA; AEFCDRH; -.
DR   OrthoDB; EOG091G06R8; -.
DR   PhylomeDB; P17735; -.
DR   TreeFam; TF105999; -.
DR   BioCyc; MetaCyc:HS06761-MONOMER; -.
DR   Reactome; R-HSA-71182; Phenylalanine and tyrosine catabolism.
DR   UniPathway; UPA00139; UER00338.
DR   ChiTaRS; TAT; human.
DR   EvolutionaryTrace; P17735; -.
DR   GenomeRNAi; 6898; -.
DR   PRO; PR:P17735; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000198650; -.
DR   CleanEx; HS_TAT; -.
DR   ExpressionAtlas; P17735; baseline and differential.
DR   Genevisible; P17735; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0016597; F:amino acid binding; IEA:Ensembl.
DR   GO; GO:0080130; F:L-phenylalanine:2-oxoglutarate aminotransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004838; F:L-tyrosine:2-oxoglutarate aminotransferase activity; IDA:UniProtKB.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IEA:InterPro.
DR   GO; GO:0006103; P:2-oxoglutarate metabolic process; IDA:UniProtKB.
DR   GO; GO:0009058; P:biosynthetic process; IEA:InterPro.
DR   GO; GO:0006536; P:glutamate metabolic process; IDA:UniProtKB.
DR   GO; GO:0006559; P:L-phenylalanine catabolic process; TAS:Reactome.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0046689; P:response to mercury ion; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0006572; P:tyrosine catabolic process; IDA:UniProtKB.
DR   Gene3D; 3.40.640.10; -; 1.
DR   Gene3D; 3.90.1150.10; -; 1.
DR   InterPro; IPR004839; Aminotransferase_I/II.
DR   InterPro; IPR004838; NHTrfase_class1_PyrdxlP-BS.
DR   InterPro; IPR015424; PyrdxlP-dep_Trfase.
DR   InterPro; IPR015421; PyrdxlP-dep_Trfase_major_sub1.
DR   InterPro; IPR015422; PyrdxlP-dep_Trfase_sub2.
DR   InterPro; IPR011715; Tyr_aminoTrfase_ubiquitination.
DR   InterPro; IPR005958; TyrNic_aminoTrfase.
DR   InterPro; IPR005957; Tyrosine_aminoTrfase.
DR   Pfam; PF00155; Aminotran_1_2; 1.
DR   Pfam; PF07706; TAT_ubiq; 1.
DR   PIRSF; PIRSF000517; Tyr_transaminase; 1.
DR   SUPFAM; SSF53383; SSF53383; 1.
DR   TIGRFAMs; TIGR01264; tyr_amTase_E; 1.
DR   TIGRFAMs; TIGR01265; tyr_nico_aTase; 1.
DR   PROSITE; PS00105; AA_TRANSFER_CLASS_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Aminotransferase; Complete proteome;
KW   Disease mutation; Mental retardation; Palmoplantar keratoderma;
KW   Phenylalanine catabolism; Phosphoprotein; Polymorphism;
KW   Pyridoxal phosphate; Reference proteome; Transferase;
KW   Tyrosine catabolism.
FT   CHAIN         1    454       Tyrosine aminotransferase.
FT                                /FTId=PRO_0000123887.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000250|UniProtKB:P04694}.
FT   MOD_RES     280    280       N6-(pyridoxal phosphate)lysine.
FT   MOD_RES     448    448       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VARIANT      70     70       N -> D (in dbSNP:rs16973344).
FT                                /FTId=VAR_048226.
FT   VARIANT     362    362       G -> V (in TYRSN2; dbSNP:rs28934277).
FT                                {ECO:0000269|PubMed:1357662}.
FT                                /FTId=VAR_000560.
FT   MUTAGEN     294    294       I->A: Reduced catalytic activity.
FT                                {ECO:0000269|PubMed:16640556}.
FT   TURN         81     84       {ECO:0000244|PDB:3DYD}.
FT   STRAND       85     87       {ECO:0000244|PDB:3DYD}.
FT   HELIX        91    103       {ECO:0000244|PDB:3DYD}.
FT   STRAND      106    108       {ECO:0000244|PDB:3DYD}.
FT   HELIX       116    126       {ECO:0000244|PDB:3DYD}.
FT   HELIX       135    137       {ECO:0000244|PDB:3DYD}.
FT   STRAND      138    143       {ECO:0000244|PDB:3DYD}.
FT   HELIX       144    155       {ECO:0000244|PDB:3DYD}.
FT   STRAND      161    167       {ECO:0000244|PDB:3DYD}.
FT   HELIX       171    178       {ECO:0000244|PDB:3DYD}.
FT   STRAND      182    188       {ECO:0000244|PDB:3DYD}.
FT   HELIX       190    192       {ECO:0000244|PDB:3DYD}.
FT   HELIX       198    202       {ECO:0000244|PDB:3DYD}.
FT   STRAND      209    217       {ECO:0000244|PDB:3DYD}.
FT   TURN        219    221       {ECO:0000244|PDB:3DYD}.
FT   HELIX       227    239       {ECO:0000244|PDB:3DYD}.
FT   STRAND      244    247       {ECO:0000244|PDB:3DYD}.
FT   TURN        249    252       {ECO:0000244|PDB:3DYD}.
FT   HELIX       263    266       {ECO:0000244|PDB:3DYD}.
FT   STRAND      272    278       {ECO:0000244|PDB:3DYD}.
FT   TURN        279    281       {ECO:0000244|PDB:3DYD}.
FT   HELIX       285    287       {ECO:0000244|PDB:3DYD}.
FT   STRAND      290    295       {ECO:0000244|PDB:3DYD}.
FT   HELIX       302    316       {ECO:0000244|PDB:3DYD}.
FT   HELIX       321    333       {ECO:0000244|PDB:3DYD}.
FT   HELIX       336    359       {ECO:0000244|PDB:3DYD}.
FT   STRAND      363    366       {ECO:0000244|PDB:3DYD}.
FT   STRAND      373    378       {ECO:0000244|PDB:3DYD}.
FT   HELIX       380    382       {ECO:0000244|PDB:3DYD}.
FT   HELIX       389    400       {ECO:0000244|PDB:3DYD}.
FT   HELIX       407    410       {ECO:0000244|PDB:3DYD}.
FT   STRAND      415    420       {ECO:0000244|PDB:3DYD}.
FT   HELIX       424    441       {ECO:0000244|PDB:3DYD}.
SQ   SEQUENCE   454 AA;  50399 MW;  82B5B24F3B2CE489 CRC64;
     MDPYMIQMSS KGNLPSILDV HVNVGGRSSV PGKMKGRKAR WSVRPSDMAK KTFNPIRAIV
     DNMKVKPNPN KTMISLSIGD PTVFGNLPTD PEVTQAMKDA LDSGKYNGYA PSIGFLSSRE
     EIASYYHCPE APLEAKDVIL TSGCSQAIDL CLAVLANPGQ NILVPRPGFS LYKTLAESMG
     IEVKLYNLLP EKSWEIDLKQ LEYLIDEKTA CLIVNNPSNP CGSVFSKRHL QKILAVAARQ
     CVPILADEIY GDMVFSDCKY EPLATLSTDV PILSCGGLAK RWLVPGWRLG WILIHDRRDI
     FGNEIRDGLV KLSQRILGPC TIVQGALKSI LCRTPGEFYH NTLSFLKSNA DLCYGALAAI
     PGLRPVRPSG AMYLMVGIEM EHFPEFENDV EFTERLVAEQ SVHCLPATCF EYPNFIRVVI
     TVPEVMMLEA CSRIQEFCEQ HYHCAEGSQE ECDK
//
